ProCE Banner Activity

My Take: Integrating Biosimilars Into an Oncology Practice

Clinical Thought
Multiple biosimilars are now approved for the treatment of active cancers. Here’s what oncologists need to know.

Released: January 18, 2018

Expiration: January 17, 2019

No longer available for credit.

Share

Faculty

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an independent educational grant from

Boehringer Ingelheim

Faculty Disclosure

Primary Author

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support paid to her institution from Biotheranostics, Eisai, Genentech/Roche, GTx, Immunomedics, Incyte, Lilly, MacroGenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon.